Warfarin, a commonly used anti-clotting drug, sold under the brand name of Coumadin, has a been a poster child for the promise of pharmacogenomics and personalized medicine. The excitement has come from the idea that knowing a patient's genotype, in this case for the VKORC1 and CYP2C9 genes, would allow ...
The New York Times had a great article a couple of days ago on the need for personalized medicine to become more than a catchy phrase. As we're learning more about the interaction between genes and drug metabolism, we're also learning that large numbers of people are either taking the ...
